MENLO PARK, Calif. — March 5, 2026 — Leads & Copy — PacBio (NASDAQ: PACB) has appointed Christopher Gibson, Ph.D., to its Board of Directors.
Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company known for its AI-driven drug discovery platforms.
According to PacBio CEO Christian Henry, Dr. Gibson has demonstrated how AI, automation, and high-dimensional biological data can transform scientific discovery. Henry added that as HiFi sequencing datasets grow in scale, the ability to leverage the full power of the HiFi genome through advanced analytics is becoming increasingly strategic.
Dr. Gibson’s experience in building and scaling an AI-native life sciences company will directly support PacBio’s long-term vision of integrating sequencing, computation, and data-driven discovery, according to Henry.
Dr. Gibson oversaw the development of a proprietary data platform at Recursion. The platform is capable of generating and analyzing multimodal datasets spanning drug discovery, translation, clinical, and electronic health records (EHR), enabling the training of machine learning models to map complex biological relationships and accelerate clinical development and patient selection.
Dr. Gibson said he is honored to join PacBio’s Board of Directors. He believes that PacBio’s high-quality, long-read sequencing generates the richest biological datasets in the industry, and that algorithmic approaches based on the best data will determine the winners in the rapidly accelerating world of healthcare.
Dr. Gibson said the convergence of advanced sequencing technologies and AI-driven analytics represents a major opportunity to accelerate discovery, development, and diagnostics by unlocking new biological insight. He said he looks forward to working with PacBio’s Board of Directors and leadership team to help realize that potential.
PacBio designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Its products and technologies include HiFi long-read sequencing, which addresses solutions across a range of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, and oncology.
PacBio products are for Research Use Only and are not for use in diagnostic procedures.
Source: PacBio
